Featured Clinical Trials

Phone Number: 908-992-6400

Email: [email protected]

About the trial:

This clinical trial is studying how safe and effective a new medicine, DS-3939a, may be in patients with non-small cell lung cancer (NSCLC) and other solid tumor cancers who have had treatment before. DS-3939a is an antibody drug conjugate (ADC), a medicine with an antibody to help it find cancer cells, that is being used for the first time in humans. 

Who can participate:

Patients who have non-squamous or squamous NSCLC with or without genetic mutations will be eligible for this study.

[email protected]

About the trial:

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor daraxonrasib (RMC 6236) compared to docetaxel in patients with previously treated, locally advanced or metastatic RAS-mutated non-small cell lung cancer (NSCLC). 

Who can participate:

Key Inclusion Criteria:

• Confirmed locally advanced or metastatic non-small cell lung cancer (NSCLC)
• Documented RAS mutation status in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61).
• No prior therapy with direct RAS targeted therapy or docetaxel
• Able to take oral medications.
• No untreated central nervous system (CNS) metastases

For full eligibility criteria, please reach out to a participating provider through the learn more link below.

[email protected]

About the trial:

Advancements in small-cell lung cancer clinical trials are leading to new options for patients with extensive-stage small-cell lung cancer (ES-SCLC). This trial is evaluating a new trial drug called BNT327 to learn whether it is safe and helpful for people with this fast-growing cancer. BNT327 could help patients who don't have many choices today. More than 1,000 patients have been treated with BNT327 in clinical trials to date.

In this trial, researchers are evaluating the safety of BNT327 and whether it works when combined with standard chemotherapy drugs (etoposide and carboplatin). They will compare it to another treatment called atezolizumab when also combined with the same chemotherapy drugs. Atezolizumab is an immunotherapy already approved in multiple countries. The goal is to determine which one works better for patients who have not been treated before for extensive-stage small-cell lung cancer.

Who can participate:

This trial is looking for participants who may qualify based on their age, diagnosis, and overall health.

4 (max) key inclusion criteria:

• You are 18 years or older.
• You have been diagnosed with extensive-stage small-cell lung cancer.
• Your small-cell lung cancer is advanced or it has been at least 6 months since your last treatment for limited-stage disease.
• You have at least one tumor that can be seen on a scan.

4 (max) key exclusion criteria:

• You are pregnant or breastfeeding.
• You have already started treatment for your small-cell lung cancer within the past 6 months.
• You have a serious heart condition or uncontrolled illness that could affect your safety during the trial.
• You have active infections (like tuberculosis or hepatitis) or serious immune system conditions.
   

[email protected]

About the trial:

HARMONi-7 is a randomized, double-blinded, global Phase 3 study of ivonescimab versus pembrolizumab for the first-line treatment of metastatic non-small cell lung cancer in patients whose tumors have high PD-L1 levels. Ivonescimab is an investigational treatment, which works by blocking two separate targets in the body to decrease the cancer cells’ ability to live, grow, and spread. 

Who can participate:

You may be eligible if you have been diagnosed with stage 4 PD-L1 high NSCLC and you have not received any prior therapy.

Genmab Trial Information, Email: [email protected]

About the trial:

This is a phase 3 clinical trial designed to evaluate the safety and efficacy of an investigational treatment, acasunlimab, in combination with pembrolizumab compared to the standard chemotherapy drug docetaxel in patients with metastatic non-small cell lung cancer.

Acasunlimab is an investigational treatment called a “bispecific antibody,” a type of immunotherapy. Bispecific antibodies can bind to two different targets at the same time. Acasunlimab is designed to target two proteins, PD-L1 and 4-1BB, aiming to stimulate the immune system to fight cancer.

During the study, participants will be assigned to receive either acasunlimab and pembrolizumab by IV (intravenous) once every 6 weeks or docetaxel by IV once every 3 weeks.

Who can participate:

• Must have lung cancer that has metastasized (spread)
• Have tumors that are positive for the PD-L1 protein (a biomarker that may be predictive of response to therapy)
• Will have been previously treated with a PD-1/PD-L1-inhibitor and a platinum-containing cancer therapy administered in combination or sequentially

For comprehensive eligibility, please reach out to a participating provider

 

Brandee Colter, Local Trial Manager, [email protected]

The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with chemotherapy versus participants who receive pembrolizumab with chemotherapy. 

Who can participate:

Patients must have a confirmed KRAS G12C mutation, which occurs in ~13% of NSCLC patients, and the tumor must be PD-L1 negative.